Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01480050 · ClinicalTrials.gov registry record · Phase 1
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01480050 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 28 participants.
The verdict
NCT01480050, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the best dose of mibefradil dihydrochloride when given together with temozolomide in treating patients with glioma.
Interventions
- DRUG temozolomide
- OTHER pharmacological study
- OTHER 3'-deoxy-3'-[18F]fluorothymidine
- DRUG Mibefradil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2012-05-31 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01480050
The ClinicalTrials.gov registry entry for NCT01480050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which temozolomide is the first listed.
NCT01480050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01480050 about?
NCT01480050 is a clinical study titled "Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma". RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. ...
What is the current status of trial NCT01480050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2012-05-31. Estimated completion is 2017-06-01.
What interventions are being tested in trial NCT01480050?
The interventions under investigation include: temozolomide (DRUG), pharmacological study (OTHER), 3'-deoxy-3'-[18F]fluorothymidine (OTHER), Mibefradil (DRUG).
Who is sponsoring clinical trial NCT01480050?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.